Vous avez cherché: esrd (Danois - Anglais)

esrd *
esrd*

hæmodialyse (esrd)
haemodialysis (esrd)

nedsat nyrefunktion og terminal nyresygdom (esrd)
renal impairment and end stage renal disease (esrd)

der er begrænsede erfaringer med patienter med esrd i hæmodialyse.
there is limited experience in patients with esrd on haemodialysis.

dialyse havde minimal virkning på koncentrationen hos patienter med esrd.
dialysis had a minimal effect on exposure in subjects with esrd.

til patienter med esrd skal sebivo indgives efter hæmodialyse (se pkt.
for patients with esrd, sebivo should be administered after haemodialysis (see section 5.2).

dosisjustering er ikke nødvendig for patienter med nedsat nyrefunktion, herunder forsøgspersoner med esrd.
no dose adjustment is necessary for patients with renal impairment, including subjects with esrd.

dosisjustering anbefales til patienter med moderat og svært nedsat nyrefunktion og hos patienter med esrd.
dose adjustment is recommended for patients with moderate and severely impaired renal function and in patients with esrd.

metabolisme kan derimod spille en mere betydningsfuld rolle ved eliminationen af sitagliptin ved svær nyreinsufficiens eller esrd.
metabolism may play a more significant role in the elimination of sitagliptin in the setting of severe renal insufficiency or esrd.

auc0-inf for gs-331007 hos personer med esrd kunne ikke bestemmes på pålidelig vis.
the auc0-inf of gs-331007 in subjects with esrd could not be reliably determined.

derfor er dosisjustering ikke påkrævet, hvis administration af aliskiren til esrd-patienter i hæmodialyse skønnes nødvendig.
therefore, if administration of aliskiren in esrd patients receiving haemodialysis is considered necessary, no dose adjustment is warranted in these patients.

21 itraconazol, ritonavir, clarithromycin) muligvis ændre sitagliptins farmakokinetik hos patienter med svær nyreinsufficiens eller esrd.
for this reason, it is possible that potent cyp3a4 inhibitors (i. e., ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the phamacokinetics of sitagliptin in patients with severe renal insufficiency or esrd.

< 30 ml/min/1,73 m2) eller esrd, der kræver hæmodialyse.
<30 ml/min/1.73 m2) or esrd requiring haemodialysis.

det er ikke nødvendigt at justere dosis hos patienter med nedsat nyrefunktion, herunder patienter med nyresygdom i slutstadiet (esrd).
no dosage adjustment is necessary for patients with renal impairment, including patients with end stage renal disease (esrd).

derfor kan potente cyp3a4- hæmmere (dvs. ketoconazol, itraconazol, ritonavir, clarithromycin) muligvis ændre sitagliptins farmakokinetik hos patienter med svær nyreinsufficiens eller esrd.
for this reason, it is possible that potent cyp3a4 inhibitors (i. e. ketoconazole, itraconazole, ritonavir, clarithromycin) could alter the phamacokinetics of sitagliptin in patients with severe renal insufficiency or esrd.